Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Twelve healthy babies born following 'safer' IVF hormone treatment

28 July 2014

By Purvi Shah

Appeared in BioNews 764

Twelve healthy babies have been born after trials of a hormone treatment called kisspeptin that has been hailed as a safer way to mature women's eggs prior to IVF.

Currently, women are given an injection of a hormone called human chorionic gonadotrophin (hCG) to stimulate egg production before IVF. The method tested in this study uses a naturally occurring hormone called kisspeptin-54 that stimulates the release of other reproductive hormones, triggering egg production in a 'gentler' way.

Researchers hope that kisspeptin-54 can offer safer IVF treatment by reducing the need for hCG, which carries the risk of causing ovarian hyperstimulation syndrome (OHSS). OHSS is where the ovaries produce too many eggs, which happens in around ten percent of women and can lead to ovarian pain, nausea, and in severe cases, death. Unlike hCG, which remains in the blood for a long time after an injection, kisspeptin is broken down more quickly, in turn lowering the risk of overstimulation and OHSS.

'OHSS is a major medical problem. It can be fatal in severe cases and it occurs in women undergoing IVF treatment who are otherwise very healthy. We really need more effective natural triggers for egg maturation during IVF treatment, and the results of this trial are very promising', said Professor Waljit Dhillo from Imperial College London, who led the study.

In this small-scale study, 53 women were given a single injection of kisspeptin-54 to induce ovulation. Mature eggs developed in 51 out of 53 participants. Forty-nine women had one or two fertilised embryos transferred to the uterus, and 12 became pregnant.

Scientists at Imperial College London will now carry out a second study in women with polycystic ovary syndrome, who have the highest risk of OHSS. Further studies will be required to investigate the full risk and safety of this treatment but also whether it leads to similar success rates in terms of fertilisation and healthy births as the current technique.

Mr Yacoub Khalaf, director of the assisted conception unit at Guy's Hospital, told the BBC: 'Whilst it is plausible that the risk of hyperstimulation syndrome could be reduced following use of kisspeptin, the number of patients studied is too small to demonstrate reduction in the incidence'. He added that 'more clinical data is needed to demonstrate that kisspeptin is not just safe but also does not reduce the chance of a pregnancy'.

SOURCES & REFERENCES
NHS Choices | 21 July 2014
 
Daily Telegraph | 19 July 2014
 
Journal of Clinical Investigation | 18 July 2014
 
Imperial College London (press release) | 18 July 2014
 
BBC News | 19 July 2014
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

15 August 2016 - by Dr Barbara Kramarz 
Women with polycystic ovary syndrome who undergo IVF using frozen embryos are more likely to have successful pregnancies than those using fresh embryos, a study suggests...
16 March 2015 - by Dr Katie Howe 
A team of Spanish researchers has developed a test that could improve IVF success rates by identifying the optimal timing for embryo transfer....
27 October 2014 - by Dr Linda Wijlaars 
An IVF method using an in-body incubator is safe and effective, research presented at the American Society for Reproductive Medicine annual meeting shows...

24 June 2013 - by Siobhan Chan 
A new IVF hormone treatment that has resulted in the birth of a baby boy could make IVF less risky, scientists report...
22 March 2009 - by Sarah Pritchard 
A group of scientists at Imperial College London have found that administration of the recently discovered protein 'kisspeptin' could 'restore fertility' for some women and form the basis for a new fertility treatment. The findings of the research, presented at the annual Society for Endocrinology BES (British...
13 March 2007 - by Heidi Nicholl 
Scientists at Imperial College, London have trialled a potential new treatment for infertility in healthy female volunteers. Kisspeptin is a reproductive hormone discovered in the town of Hershey, Pennsylvania and named after the town's most famous export ('Hershey's Kisses' chocolates). Mutations in the receptor for Kisspeptin result...
07 February 2005 - by BioNews 
Puberty starts when a key gene called KiSS-1 switches on, US researchers say. The team, based at the University of Pittsburgh, say that the gene makes a protein that switches on another gene, which then triggers the production of reproductive hormones. The research, published in the journal Proceedings of...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation